Hogan Lovells

With several offices throughout the US and around the globe, Hogan Lovells maintains a strong international presence in the life sciences industry. The firm advises clients in the sector on all matters related to financing, licensing, and transactions. A peer praises the firm for its "strong regulatory group supporting the transactional practices," and "excellent, deep knowledge of the life sciences industry."

Based in Baltimore, Asher Rubin is global head of the firm's life sciences group and "pretty strong" in the space, according to one peer. He recently advised Tesaro on its $5.1 billion acquisition by GlaxoSmithKline. Rubin was shortlisted by LMG Life Sciences for the Corporate Attorney of the Year award in 2019.

Adam Golden is head of the life sciences corporate group and is highly regarded in the field, representing clients in several high-profile transactions as well as collaboration agreements. He recently represented Celgene in its strategic collaboration with Obsidian Therapeutics, and served as corporate counsel to Novartis in its $8.7 billion acquisition of AveXis. A peer notes Golden for his "deep experience and superior knowledge of the life sciences," and is "always at the cutting-edge of developments."

Philadelphia-based Steve Abrams assists a variety of life sciences companies with corporate financing, transactions, licensing agreements and collaborations. Abrams recently assisted in initial public offerings for Arbutus Biopharma and EyePoint Pharmaceuticals.

Hogan Lovells is an international firm with a full-service practice in the life sciences area. The firm is notable for its all-encompassing regulatory practice, for which it receives top rankings across the board. The life sciences group also receives high ratings for its practices in M&A, licensing and collaboration and white-collar matters.

The firm's top-ranked regulatory practice includes "terrific" partner David Fox, who is highly regarded as an advisor to pharmaceutical companies in FDA clearance. He is currently representing AllerQuest in its FDA approval process for developing an innovative penicillin allergy test. Medical device advisor Jonathan Kahan boasts more than 40 years of experience practicing law. He is currently assisting Hitachi with FDA market clearance for its proton beam therapy (PBT) systems. In the pricing and reimbursement arena, Alice Valder Curran is widely considered one of the standouts in her field. She currently serves as chair of the firm's global regulatory practice. Another standout is Beth Roberts, who has a "stellar reputation" in reimbursement matters for life sciences companies.

A peer praises the firm for its "strong regulatory group supporting the transactional practices," and "excellent, deep knowledge of the life sciences industry" as it relates to corporate matters. Asher Rubin is global head of the firm's life sciences group, who recently advised Tesaro in its $5.1 billion acquisition by GlaxoSmithKline. Rubin was shortlisted by LMG Life Sciences for the Corporate Attorney of the Year award in 2019. Adam Golden is head of the life sciences corporate group and is well known for his representation of clients in high-profile transactions and collaboration agreements. He recently represented Celgene in its strategic collaboration with Obsidian Therapeutics. Steve Abrams assists a variety of life sciences companies with corporate financing, transactions, licensing agreements and collaborations. He recently assisted in initial public offerings for Arbutus Biopharma and EyePoint Pharmaceuticals.

Jonathan Diesenhaus has extensive experience advising a number of life science clients involving criminal investigations and enforcement matters. Among his current clients, Diesenhaus represents William Beaumont Hospital in a multi-year investigation and associated qui tam litigation brought by the Department of Justice. Leading appellate practitioner Neal Katyal recently acted for Bristol-Myers Squibb and Pfizer in a multidistrict litigation that challenged the labeling of the clients' anticoagulant drug Eliquis, resulting in a successful dismissal with the verdict upheld on appeal. Lauren Colton recently represented Amgen as lead counsel in a number of product liability suits related to the client's biologic product Enbrel. Colton serves as head of the firm's products law practice group.

For IP matters, Arlene Chow is one of the firm's leading life sciences practitioners, with a deep focus on the biotechnology and pharmaceutical areas. She specializes in contentious proceedings before the Patent Office, an area of continued focus in her practice. According to a client, Chow has "a very deep knowledge of the law and the science and the industry. [Her] skills in depositions and at oral hearings are superb." Chow is currently handling IPR proceedings for Merck related to patents covering pneumococcal vaccine Prevnar 13.

DC-based Hogan Lovells is a global, full-service law firm that is widely considered a juggernaut in the life sciences industry, with its team of experts versed in antitrust litigation, white-collar defense and regulatory enforcement.

Jonathan Diesenhaus has extensive experience advising life science clients in criminal investigations and enforcement matters. Among his current representations, Diesenhaus is counsel for William Beaumont Hospital in a multi-year investigation and associated qui tam litigation by the Department of Justice. The claims involve alleged violations of the False Claims Act, Stark Law, and Anti-Kickback Statute.

Recently involved in the product liability space is Neal Katyal, who has earned his status as a leading appellate litigator with a strong track record in life sciences disputes. He recently represented Bristol-Myers Squibb (BMS) and Pfizer in a multi-district litigation that challenged the labeling of the clients' anticoagulant drug Eliquis. The case resulted in a successful dismissal with the verdict upheld on appeal. Prior to his private practice at Hogan Lovells, Katyal served as Solicitor General of the United States.

Co-headquartered in London and Washington DC, Hogan Lovells is consistently ranked for having one of the premier life sciences regulatory practices. One client describes the firm as being "top-notch," with a group of attorneys who possess "a very deep knowledge of the law." The firm's depth gives it the ability to assist a variety of life sciences clients in all aspects of the regulatory process.

David Fox is highly regarded for assisting a number of pharmaceutical companies with their regulatory issues. One peer comments that Fox is "terrific," while another describes him as an "absolute star" in the field. Among his current clients, Fox is representing AllerQuest in its FDA approval process for developing an innovative penicillin allergy test.

Operating from both the firm's Washington, DC and Denver offices, Meredith Manning has over 20 years of experience counseling a variety of pharmaceutical clients in regulatory matters. One clients exclaims that Manning and her team "are extremely competent and knowledgeable on FDA regulatory matters" and are "responsive, thorough and able to explain complex rules in an understandable way."

Jonathan Kahan is a "star" according to one peer, and has over 40 years of experience assisting medical device and diagnostics companies with their regulatory issues. Kahan is currently representing Hitachi with FDA market clearance for its proton beam therapy (PBT) systems.

In the pricing and reimbursement arena, Alice Valder Curran is widely considered one of the standouts in her field. She regularly advises clients on matters related to the Medicaid Drug Rebate Program, the Medicare average sales price (ASP) reporting requirement, and the Health Resources and Services Administration (HRSA) drug pricing program. Valder Curran currently serves as chair of the firm's global regulatory practice. Beth Roberts has a "stellar reputation" according to one peer, and has over 20 years of experience assisting life sciences clients in reimbursement matters.